{"success":true,"data":{"pressRelease":{"id":"24802","rtpr_id":"nGNX7hQ2TR","ticker":"CPRX","exchange":"NASDAQ","all_tickers":["CPRX"],"title":"Angelini Pharma to Acquire Catalyst Pharmaceuticals for 4.1 Billion USD (3.5 Billion Euros), Entering the U.S. Market and Consolidating its Leadership in Brain Health and Rare Disease","author":"Globe Newswire","published_at":"2026-05-07T06:14:03.718Z","article_body":"* The Boards of Directors of Angelini Pharma and Catalyst Pharmaceuticals have\nunanimously approved the acquisition of Catalyst Pharmaceuticals at 31.50 USD\nper share in cash, for a total consideration of approximately 4.1 billion USD,\nrepresenting a premium of 28% to the 30-day volume-weighted average trading\nprice as of April 22, 2026\n* The transaction marks Angelini Pharma's entry into the U.S. market,\nreinforcing its long-term commitment to Brain Health and its dedication to\npeople living with Rare Diseases \n* Closing is expected in the third quarter of 2026\nROME and CORAL GABLES, Fla., May 07, 2026 (GLOBE NEWSWIRE) -- Angelini Pharma\nS.p.A. (“Angelini Pharma”), an international pharmaceutical company and\npart of the Angelini Industries Group, and Catalyst Pharmaceuticals, Inc.\n(\"Catalyst\") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company\nfocused on in-licensing, developing, and commercializing novel medicines for\npatients living with rare and difficult-to-treat diseases, today announced\nthat they have entered into a definitive agreement pursuant to which Angelini\nPharma has agreed to acquire all outstanding shares of Catalyst for 31.50 USD\nper share in cash, for a total equity value of approximately 4.1 billion USD\n(equivalent to 3.5 billion euros) which represents a 21% premium to\nCatalyst’s unaffected closing share price on April 22, 2026, the last\ntrading day before market signs that the transaction had become public\ninformation, as well as a 28% premium to the 30-day volume-weighted average\ntrading price to that unaffected date. The transaction has been unanimously\napproved by the Boards of Directors of both companies and is expected to close\nin the third quarter of 2026.\n\nThis acquisition marks a pivotal moment in the Angelini Group’s history —\na group with over 100 years of history, chaired by Thea Paola Angelini, a\nfourth-generation member of the Angelini family — led by Sergio Marullo di\nCondojanni, Chief Executive Officer of Angelini Pharma.\n\nThe transaction will be carried out with the participation of Blackstone funds\nand select international partners, and will be financed with the support of\nBNP Paribas, acting as Sole Global Coordinator and Underwriter of the\nfinancing package.\n\nFounded in 2002 and listed on Nasdaq since 2006, Catalyst has built a robust\nportfolio of products focused on the treatment of rare neuromuscular and\nneurological diseases: FIRDAPSE(®) (amifampridine), the only evidence-based\ntreatment approved by the U.S. Food and Drug Administration (FDA) for\nLambert-Eaton myasthenic syndrome (LEMS) in patients aged six and above;\nAGAMREE(®) (vamorolone) a novel corticosteroid approved by the FDA in 2023\nfor the treatment of Duchenne Muscular Dystrophy (DMD) in patients aged 2 and\nabove; and FYCOMPA(®) (perampanel), an antiepileptic drug approved for the\ntreatment of partial-onset seizures and primary generalised tonic-clonic\nseizures, the U.S. rights to which were acquired from Eisai in 2023.\n\nFollowing completion of the acquisition, Angelini Pharma intends to integrate\nCatalyst’s portfolio and exceptional commercial infrastructure with its own\nexpertise and products in Brain Health to develop a next-generation\ntherapeutic platform in Rare Diseases. This transaction reinforces the\ncommitment Angelini Pharma has built over recent years through products such\nas Ontozry(®) and high-profile scientific collaborations. Catalyst's\nportfolio is expected to significantly strengthen the company's strategic\nobjectives, growing its presence in the U.S. as part of a balanced strategy\nthat aims to develop the North American market while continuing to strengthen\nits core business in Europe. Angelini Pharma’s continued industrial presence\nin Italy will remain a strategic asset as a valuable production and scientific\ncenter within the combined company's global operations.\n\nSergio Marullo di Condojanni, CEO of Angelini Pharma, commented: \"Five years\nago, we embarked on a profound transformation of Angelini Pharma —\norganizational, scientific and strategic — with the ambition to build a\ncompany capable of competing at the highest global level. On one hand, we\ncontinued to invest in our traditional portfolio; on the other, we chose to\nfocus on central nervous system disorders, with the goal of addressing an\nunmet medical need that is, unfortunately, growing significantly. We invested\nin innovation through the development of a high-value asset pipeline,\nincluding collaborations with leading partners such as Blackstone Life\nSciences in GRIN Therapeutics. Today, we take another significant step with\nthe acquisition of Catalyst Pharmaceuticals, which we believe will establish\nAngelini Pharma as a relevant global player in neurological Rare Diseases.\nEntering the U.S. market will allow us to acquire the scale and capabilities\nneeded to continue this journey. Patient care remains at the heart of our\nvision. We continue to look ahead with determination, backed by a clear\nstrategy and the drive to keep growing on a global scale. We are proud of a\ntransaction that demonstrates, once again, the dynamism of the Italian\npharmaceutical industry.” \n\nRich Daly, President and CEO of Catalyst, commented: “This is a pivotal and\ntransformative moment for Catalyst, our team, and the patients we serve. By\ncombining our unique capabilities in rare diseases with Angelini’s proven\nglobal reach, we will create a stronger, scalable, and robust rare disease\nplatform to expand access to life-changing therapies worldwide. For\nshareholders, this transaction delivers immediate and certain cash value\nthrough a compelling premium. We are proud of the incredible foundation our\nteam has built and are confident that together with Angelini, we can enhance\npatient support, accelerate innovation, and continue to drive sustainable\nlong-term value for all stakeholders.” \n\nMedia Contacts\n\nAngelini Pharma\n\nRoberto Scrivo\nChief External Affairs Communication & Sustainability Officer\n+39 348 454 6502\nRoberto.scrivo@angelinipharma.com \n\nChiara Antoniucci\nGlobal External & Internal Communication Director\n+39 347 713 3926\nchiara.antoniucci@angelinipharma.com\n\nFederica Marcelli\nItaly Media Communications Manager\n+39 3383924138\nfederica.marcelli@angelinipharma.com\n\nMedia\nJemini Sedani \nReal Chemistry, Group Director, Media & Engagement\n+44 (0)7940 594788\njsedani@realchemistry.com \n\nCatalyst\nInvestors \nMelissa Kendis, Catalyst Pharmaceuticals, Inc.\n(305) 420-3200\nIR@catalystpharma.com\n\nMedia \nJed Repko / Mahmoud Siddig\nJoele Frank, Wilkinson Brimmer Katcher\n(212) 355-4449\n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/f92dd6a5-1eab-49ca-94ea-b94225630a57)\n\n\n\nGlobeNewswire, Inc. 2026","article_body_html":"","raw_payload":{"data":{"id":"nGNX7hQ2TR","title":"Angelini Pharma to Acquire Catalyst Pharmaceuticals for 4.1 Billion USD (3.5 Billion Euros), Entering the U.S. Market and Consolidating its Leadership in Brain Health and Rare Disease","author":"Globe Newswire","ticker":"CPRX","created":"2026-05-07T06:14:03.718Z","tickers":["CPRX"],"exchange":"NASDAQ","article_body":"* The Boards of Directors of Angelini Pharma and Catalyst Pharmaceuticals have\nunanimously approved the acquisition of Catalyst Pharmaceuticals at 31.50 USD\nper share in cash, for a total consideration of approximately 4.1 billion USD,\nrepresenting a premium of 28% to the 30-day volume-weighted average trading\nprice as of April 22, 2026\n* The transaction marks Angelini Pharma's entry into the U.S. market,\nreinforcing its long-term commitment to Brain Health and its dedication to\npeople living with Rare Diseases \n* Closing is expected in the third quarter of 2026\nROME and CORAL GABLES, Fla., May 07, 2026 (GLOBE NEWSWIRE) -- Angelini Pharma\nS.p.A. (“Angelini Pharma”), an international pharmaceutical company and\npart of the Angelini Industries Group, and Catalyst Pharmaceuticals, Inc.\n(\"Catalyst\") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company\nfocused on in-licensing, developing, and commercializing novel medicines for\npatients living with rare and difficult-to-treat diseases, today announced\nthat they have entered into a definitive agreement pursuant to which Angelini\nPharma has agreed to acquire all outstanding shares of Catalyst for 31.50 USD\nper share in cash, for a total equity value of approximately 4.1 billion USD\n(equivalent to 3.5 billion euros) which represents a 21% premium to\nCatalyst’s unaffected closing share price on April 22, 2026, the last\ntrading day before market signs that the transaction had become public\ninformation, as well as a 28% premium to the 30-day volume-weighted average\ntrading price to that unaffected date. The transaction has been unanimously\napproved by the Boards of Directors of both companies and is expected to close\nin the third quarter of 2026.\n\nThis acquisition marks a pivotal moment in the Angelini Group’s history —\na group with over 100 years of history, chaired by Thea Paola Angelini, a\nfourth-generation member of the Angelini family — led by Sergio Marullo di\nCondojanni, Chief Executive Officer of Angelini Pharma.\n\nThe transaction will be carried out with the participation of Blackstone funds\nand select international partners, and will be financed with the support of\nBNP Paribas, acting as Sole Global Coordinator and Underwriter of the\nfinancing package.\n\nFounded in 2002 and listed on Nasdaq since 2006, Catalyst has built a robust\nportfolio of products focused on the treatment of rare neuromuscular and\nneurological diseases: FIRDAPSE(®) (amifampridine), the only evidence-based\ntreatment approved by the U.S. Food and Drug Administration (FDA) for\nLambert-Eaton myasthenic syndrome (LEMS) in patients aged six and above;\nAGAMREE(®) (vamorolone) a novel corticosteroid approved by the FDA in 2023\nfor the treatment of Duchenne Muscular Dystrophy (DMD) in patients aged 2 and\nabove; and FYCOMPA(®) (perampanel), an antiepileptic drug approved for the\ntreatment of partial-onset seizures and primary generalised tonic-clonic\nseizures, the U.S. rights to which were acquired from Eisai in 2023.\n\nFollowing completion of the acquisition, Angelini Pharma intends to integrate\nCatalyst’s portfolio and exceptional commercial infrastructure with its own\nexpertise and products in Brain Health to develop a next-generation\ntherapeutic platform in Rare Diseases. This transaction reinforces the\ncommitment Angelini Pharma has built over recent years through products such\nas Ontozry(®) and high-profile scientific collaborations. Catalyst's\nportfolio is expected to significantly strengthen the company's strategic\nobjectives, growing its presence in the U.S. as part of a balanced strategy\nthat aims to develop the North American market while continuing to strengthen\nits core business in Europe. Angelini Pharma’s continued industrial presence\nin Italy will remain a strategic asset as a valuable production and scientific\ncenter within the combined company's global operations.\n\nSergio Marullo di Condojanni, CEO of Angelini Pharma, commented: \"Five years\nago, we embarked on a profound transformation of Angelini Pharma —\norganizational, scientific and strategic — with the ambition to build a\ncompany capable of competing at the highest global level. On one hand, we\ncontinued to invest in our traditional portfolio; on the other, we chose to\nfocus on central nervous system disorders, with the goal of addressing an\nunmet medical need that is, unfortunately, growing significantly. We invested\nin innovation through the development of a high-value asset pipeline,\nincluding collaborations with leading partners such as Blackstone Life\nSciences in GRIN Therapeutics. Today, we take another significant step with\nthe acquisition of Catalyst Pharmaceuticals, which we believe will establish\nAngelini Pharma as a relevant global player in neurological Rare Diseases.\nEntering the U.S. market will allow us to acquire the scale and capabilities\nneeded to continue this journey. Patient care remains at the heart of our\nvision. We continue to look ahead with determination, backed by a clear\nstrategy and the drive to keep growing on a global scale. We are proud of a\ntransaction that demonstrates, once again, the dynamism of the Italian\npharmaceutical industry.” \n\nRich Daly, President and CEO of Catalyst, commented: “This is a pivotal and\ntransformative moment for Catalyst, our team, and the patients we serve. By\ncombining our unique capabilities in rare diseases with Angelini’s proven\nglobal reach, we will create a stronger, scalable, and robust rare disease\nplatform to expand access to life-changing therapies worldwide. For\nshareholders, this transaction delivers immediate and certain cash value\nthrough a compelling premium. We are proud of the incredible foundation our\nteam has built and are confident that together with Angelini, we can enhance\npatient support, accelerate innovation, and continue to drive sustainable\nlong-term value for all stakeholders.” \n\nMedia Contacts\n\nAngelini Pharma\n\nRoberto Scrivo\nChief External Affairs Communication & Sustainability Officer\n+39 348 454 6502\nRoberto.scrivo@angelinipharma.com \n\nChiara Antoniucci\nGlobal External & Internal Communication Director\n+39 347 713 3926\nchiara.antoniucci@angelinipharma.com\n\nFederica Marcelli\nItaly Media Communications Manager\n+39 3383924138\nfederica.marcelli@angelinipharma.com\n\nMedia\nJemini Sedani \nReal Chemistry, Group Director, Media & Engagement\n+44 (0)7940 594788\njsedani@realchemistry.com \n\nCatalyst\nInvestors \nMelissa Kendis, Catalyst Pharmaceuticals, Inc.\n(305) 420-3200\nIR@catalystpharma.com\n\nMedia \nJed Repko / Mahmoud Siddig\nJoele Frank, Wilkinson Brimmer Katcher\n(212) 355-4449\n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/f92dd6a5-1eab-49ca-94ea-b94225630a57)\n\n\n\nGlobeNewswire, Inc. 2026"},"type":"article","timestamp":"2026-05-07T06:14:03.757619716Z","server_sent_at_ms":1778134443757},"received_at":"2026-05-07T06:14:03.808Z","source_url":"https://www.globenewswire.com/news-release/2026/05/07/3289628/0/en/angelini-pharma-to-acquire-catalyst-pharmaceuticals-for-4-1-billion-usd-3-5-billion-euros-entering-the-u-s-market-and-consolidating-its-leadership-in-brain-health-and-rare-disease.html"},"analysis":{"id":"19407","press_release_id":"24802","analysis_json":{"industry":{"label":"Pharmaceuticals, Biotechnology & Life Sciences","sector":"Health Care"},"redFlags":[],"eventType":"m_and_a","narrative":"Angelini Pharma has agreed to acquire Catalyst Pharmaceuticals for $31.50 per share in cash, valuing the company at approximately $4.1 billion.\n\nThe offer represents a 28% premium to the 30-day volume-weighted average price and a 21% premium to the unaffected closing share price as of April 22, 2026.\n\nThe transaction is expected to close in the third quarter of 2026 and is backed by financing from BNP Paribas and Blackstone funds.","sentiment":"bullish","agentHooks":{"shouldPost":true,"suggestedAngle":"Catalyst agrees to be acquired by Angelini Pharma at a 28% premium to VWAP for $4.1B in cash."},"keyFigures":{"dealValueUsd":4100000000,"offeringPrice":31.5,"customDimensions":{"premium_to_vwap":"28%","premium_to_unaffected_close":"21%"}},"quotedText":"This is a pivotal and transformative moment for Catalyst, our team, and the patients we serve.","namedEntities":{"people":[{"name":"Sergio Marullo di Condojanni","role":"CEO of Angelini Pharma"},{"name":"Thea Paola Angelini","role":"Chair of Angelini Group"},{"name":"Rich Daly","role":"President and CEO of Catalyst"},{"name":"Roberto Scrivo","role":"Chief External Affairs Communication & Sustainability Officer"},{"name":"Chiara Antoniucci","role":"Global External & Internal Communication Director"},{"name":"Federica Marcelli","role":"Italy Media Communications Manager"},{"name":"Jemini Sedani","role":"Group Director, Media & Engagement, Real Chemistry"},{"name":"Melissa Kendis","role":"Investor Contact, Catalyst"},{"name":"Jed Repko","role":"Media Contact, Joele Frank"},{"name":"Mahmoud Siddig","role":"Media Contact, Joele Frank"}],"products":["FIRDAPSE","amifampridine","AGAMREE","vamorolone","FYCOMPA","perampanel","Ontozry"],"companies":[{"name":"Angelini Pharma S.p.A.","relationship":"acquirer"},{"name":"Catalyst Pharmaceuticals, Inc.","ticker":"CPRX","relationship":"target"},{"name":"Blackstone","relationship":"financing participant"},{"name":"BNP Paribas","relationship":"financing coordinator/underwriter"},{"name":"Eisai","relationship":"licensor"},{"name":"Joele Frank, Wilkinson Brimmer Katcher","relationship":"advisor"},{"name":"Real Chemistry","relationship":"agency"}],"dollarAmounts":[{"amount":"31.50 USD","context":"per share acquisition price"},{"amount":"4.1 billion USD","context":"total transaction consideration / equity value"},{"amount":"3.5 billion euros","context":"total transaction consideration in EUR"}]},"materialImpact":{"score":5,"reasoning":"Definitive agreement to sell the company for $31.50 per share in cash, representing a 28% premium to the 30-day VWAP. This is a binary M&A event that removes future trading risk for shareholders."},"tickerRelevance":{"others":[],"primary":"CPRX"},"globalImportance":65,"audienceRelevance":50,"eventTypeSecondary":[],"importanceComponents":{"tickerTier":"Mid-cap","eventGravity":"M&A announcement, $4.1B deal value","sectorWeight":"Biotech/Pharma","marketCapAdjustment":"Significant premium relative to recent trading"}},"event_type":"m_and_a","event_type_secondary":null,"sentiment":"bullish","material_impact_score":5,"narrative":"Angelini Pharma has agreed to acquire Catalyst Pharmaceuticals for $31.50 per share in cash, valuing the company at approximately $4.1 billion.\n\nThe offer represents a 28% premium to the 30-day volume-weighted average price and a 21% premium to the unaffected closing share price as of April 22, 2026.\n\nThe transaction is expected to close in the third quarter of 2026 and is backed by financing from BNP Paribas and Blackstone funds.","key_figures":{"dealValueUsd":4100000000,"offeringPrice":31.5,"customDimensions":{"premium_to_vwap":"28%","premium_to_unaffected_close":"21%"}},"named_entities":{"people":[{"name":"Sergio Marullo di Condojanni","role":"CEO of Angelini Pharma"},{"name":"Thea Paola Angelini","role":"Chair of Angelini Group"},{"name":"Rich Daly","role":"President and CEO of Catalyst"},{"name":"Roberto Scrivo","role":"Chief External Affairs Communication & Sustainability Officer"},{"name":"Chiara Antoniucci","role":"Global External & Internal Communication Director"},{"name":"Federica Marcelli","role":"Italy Media Communications Manager"},{"name":"Jemini Sedani","role":"Group Director, Media & Engagement, Real Chemistry"},{"name":"Melissa Kendis","role":"Investor Contact, Catalyst"},{"name":"Jed Repko","role":"Media Contact, Joele Frank"},{"name":"Mahmoud Siddig","role":"Media Contact, Joele Frank"}],"products":["FIRDAPSE","amifampridine","AGAMREE","vamorolone","FYCOMPA","perampanel","Ontozry"],"companies":[{"name":"Angelini Pharma S.p.A.","relationship":"acquirer"},{"name":"Catalyst Pharmaceuticals, Inc.","ticker":"CPRX","relationship":"target"},{"name":"Blackstone","relationship":"financing participant"},{"name":"BNP Paribas","relationship":"financing coordinator/underwriter"},{"name":"Eisai","relationship":"licensor"},{"name":"Joele Frank, Wilkinson Brimmer Katcher","relationship":"advisor"},{"name":"Real Chemistry","relationship":"agency"}],"dollarAmounts":[{"amount":"31.50 USD","context":"per share acquisition price"},{"amount":"4.1 billion USD","context":"total transaction consideration / equity value"},{"amount":"3.5 billion euros","context":"total transaction consideration in EUR"}]},"model_name":"glm-4.7","prompt_hash":"sha256:f66160e0fe5301b2","schema_hash":"sha256:12363694422af5d9","created_at":"2026-05-07T18:22:44.913Z","global_importance":65,"audience_relevance":50,"importance_components":{"tickerTier":"Mid-cap","eventGravity":"M&A announcement, $4.1B deal value","sectorWeight":"Biotech/Pharma","marketCapAdjustment":"Significant premium relative to recent trading"}},"durationMs":null,"modelName":"glm-4.7"}}